news
Researchers develop open access database on macrolactones
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
List view / Grid view
Hepatitis C
news
Better HIV, lupus and hep C treatments possible with malaria discovery
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
news
Gene transcription in CD8 T cells differentiates chronic from resolving HCV
Researchers have identified differences in gene transcription within key immune cells that may distinguish those individuals infected with HCV...
news
Daiichi Sankyo to collaborate on drugs for neglected tropical diseases
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
news
Experimental hepatitis C drug slows Zika virus infection in mice
17 May 2016 | By Katie Sadler
Virologists have discovered that an antiviral drug against hepatitis C has helped slow down the development of Zika virus in Mice.
news
Abbott and UCSF discover human pegivirus 2 linked to HCV
14 December 2015 | By Victoria White
Their research identified eight complete strains of human pegivirus 2, which makes it the first study to reveal the entire genetic makeup of this new virus...
news
VBI Vaccines presents data supporting the use of its eVLP platform to develop a novel HCV vaccine candidate
4 June 2015 | By Victoria White
VBI Vaccines has delivered a presentation that supports the potential use of its eVLP platform in the development of a novel Hepatitis C vaccine candidate...
news
Janssen and Achillion enter into worldwide collaboration to combat Hepatitis C
22 May 2015 | By Victoria White
Achillion and Janssen have entered into a worldwide license and collaboration arrangement to develop and commercialise one or more of Achillion's HCV assets...
news
Partnering for Cure programme announces new winning projects designed to investigate novel ways to cure viral diseases
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
news
The end of hepatitis C?
6 May 2014 | By Red Door Communications
New evidence published to coincide with the International Liver Meeting showing the potential for elimination of hepatitis C across 15 countries by 2030...
news
Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR12 rates of up to 90%
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
news
New data from Phase 3 attain study of Janssen’s once-daily simeprevir compared to telaprevir in treatment-experienced adult patients with genotype 1 chronic hepatitis C
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...